Citoxlab Group, an Evreux, France-based non-clinical CRO player, is to acquire Solvo Biotechnology, a Budapest, Hungary-based CRO specializing in drug transporter studies and the assessment of Drug-Drug Interactions (DDI).
The closing of the deal will take place within the next month. The financial details were not disclosed.
Founded in 1999 and led by Ernö Duda, president and CEO, Solvo Biotechnology provides pharmaceutical and biotech companies developing small molecules to protein therapeutics prior to submission to FDA/EMA/MLHW with drug transporter research services via a staff of around 100 people, located in Budapest and Szeged, Hungary.
Through this new acquisition, Citoxlab – led by Dr. Jean-Francois Le Bigot, president and CEO – reinforces its position in the non-clinical CRO field, with consolidated sales of $167 million (€136M) and a staff of 1,300, spread over nine sites – France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas-City), Denmark (Copenhagen) and Hungary (Veszprém, and now Budapest and Szeged).
Citoxlab Group offers a comprehensive range of preclinical services to pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. The company carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. Citoxlab and Atlanbio also offer both preclinical and clinical bioanalysis and biomarker services. AccelLAB provides efficacy and safety studies in medical devices (cardiology, ENT, orthopedics, and regenerative medicine).